Jefferies London: Zymeworks had double-news during London Life Science Week - a P3 success for its HER2 bispecific in gastroesophageal cancer and it also launched a new royalty model
CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.